It was reported on Tuesday that the European Commission has granted final approval to US-based companies Mylan (NASDAQ: MYL) and Pfizer Inc (NYSE: PFE) for the proposed combination of their Upjohn business.
The European Commission offered conditional approval in April 2020 that was subject to the divestiture of certain of Mylan's products in Europe.
The European Commission approved the proposed divestiture buyers and Mylan signed the contract with those customers on terms that the European Commission has accepted. Both firms have already received approval from the Australian Competition and Consumer Commission and the New Zealand Commerce Commission related to combining this business.
Genentech's Gazyva (obinutuzumab) receives US FDA approval to treat adults with lupus nephritis
AstraZeneca wins US FDA approval for Tezspire in chronic rhinosinusitis with nasal polyps
Antengene reveals ATG-022 clinical data at ESMO 2025
WeightWatchers launches RxFlexFund to expand affordable GLP-1 access for employers and employees
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Merck reports positive Phase 3 data for investigational two-drug HIV regimen doravirine/islatravir
60 Degrees reports first patient has tested negative for babesiosis in tafenoquine study
Minovia Therapeutics' MNV-201 receives FDA Orphan Drug Designation for Myelodysplastic Syndrome